Professor Jonas Mattsson is a globally recognised authority in cell therapy, with more than 300 publications and extensive experience from both academic research and clinical practice.

Jonas Mattsson is currently Director of the Hans Messner Allogeneic Transplant Program at Princess Margaret Cancer Centre in Toronto and Professor of Medicine at the University of Toronto. He also holds the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, established as the world’s first professorship in cell therapy. Previously, he was Professor at Karolinska Institutet and Senior Consultant at Karolinska University Hospital and Oslo University Hospital.

“Neogap is developing a personalised cell therapy that addresses one of the greatest challenges in modern oncology – the ability to selectively target the unique mutations of a tumour. By using a patient’s own T cells and training them to recognise the tumour-specific targets, the therapy creates a targeted treatment with the potential to cure patients who currently have no remaining treatment options. This is particularly relevant in colorectal cancer, a major disease with rising incidence, especially among younger patients. I look forward to contributing to the company’s continued development,” says Jonas Mattsson.

“Jonas brings clinical expertise and an international perspective with deep roots in advanced cell therapy. His experience will be of great value as we progress in our clinical development programme and strengthen the company for the next stages,” says Samuel Svensson, CEO of Neogap Therapeutics.